Cartesian Growth II Common Stock

The latest common stock for RENE is $38M as of June 2026. That compares with $87M in the prior-year period — down 55.9% year over year. Investors often review this figure alongside Cartesian Growth II's historical trend and sector peers before judging valuation or financial health.

Over the past year, RENE's common stock moved from $87M to $38M — a 55.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cartesian Growth II's operating scale or balance-sheet position.

A common stock figure of $38M for RENE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting RENE's common stock ($38M), review year-over-year change from $87M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.